Table 1.
Clinical and laboratory parameters of the total ANCA GN cohort.
| Parameter | Value |
|---|---|
| Clinical data | |
| Median age (IQR) – years | 64 (54.25-73.75) |
| Female sex – no. (%) | 20 (41.7) |
| Disease onset – days before admission (IQR) | 17.5 (7-40) |
| Kidney biopsy – days after admission (IQR) | 6 (3-9) |
| ANCA subtype MPA/GPA – no. (%) | 24/24 (50/50) |
| History of vasculitis – no. (%) | 7 (14.6) |
| RRT within 30 days after admission – no. (%) | 15 (31.3) |
| AAV manifestations | |
| Median BVAS (IQR) – points | 18 (15-20) |
| Extrarenal manifestation – no. (%) | 40 (83.3) |
| Lung involvement – no. (%) | 27 (56.3) |
| Pulmonary hemorrhage – no. (%) | 7 (14.6) |
| Sinus involvement – no. (%) | 7 (14.6) |
| Joint involvement – no. (%) | 12 (25) |
| Ear involvement – no. (%) | 3 (6.3) |
| Eye involvement – no. (%) | 3 (6.3) |
| Nerve involvement – no. (%) | 6 (12.5) |
| Skin involvement – no. (%) | 9 (18.8) |
| Laboratory data | |
| ANCA subtype MPO/PR3 – no. (%) | 23 (47.9) |
| Median serum creatinine (IQR) – mg/dL | 3.06 (1.355-5.138) |
| Median eGFR (IQR) – mL/min/1.73 m2 | 18.3 (9.65-50.85) |
| Median CRP (IQR) – mg/L | 60.5 (20.05-109.5) |
| Urinary data | |
| Median uPCR (IQR) – mg/g | 940.5 (523.6-1559) |
| Median uACR (IQR) – mg/g | 451.4 (156.3-855.3) |
| Median α1-microglobulin (IQR) – mg/g | 65.9 (34.8-178.2) |
| Median α2-macroglobulin (IQR) – mg/g | 4.98 (2.903-10.3) |
| Median IgG (IQR) – mg/g | 44.33 (21.63-201.5) |
| Acanthocytes – no. (%) | 6 (12.5) |
| Histopathological subgrouping | |
| Crescentic class – no. (%) | 15 (31.3) |
| Focal class – no. (%) | 24 (50) |
| Sclerotic class – no. (%) | 3 (6.3) |
| Mixed class – no. (%) | 6 (12.5) |
| ARRS | |
| High risk – no. (%) | 7 (14.6) |
| Medium risk – no. (%) | 21 (43.8) |
| Low risk – no. (%) | 20 (41.7) |
| Total renal chronicity | |
| Score (IQR) – points | 3 (1.25-5) |
ANCA, anti-neutrophil cytoplasmic antibodies; ARRS, ANCA renal risk score; BVAS, Birmingham Vasculitis Activity Score; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate (CKD-EPI); GN, glomerulonephritis; GPA, granulomatosis with polyangiitis; IQR, interquartile range; MPA, microscopic polyangiitis; MPO, myeloperoxidase; no., number; PR3, proteinase 3; RRT, renal replacement therapy; uPCR, urinary protein-to-creatinine ratio; uACR, urinary albumin-to-creatinine ratio.